Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for cognitive performance during electroconvulsive therapy
IRCT20200207046404N1Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Oct 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia, schizoaffective disorder, affective disorder and 1 more comparing Galantamine + electroconvulsive therapy with Placebo + electroconvulsive therapy (2 arms). Primary endpoints: Memory, Wechsler test score and 1 more. Started Oct 2018; status: completed.
02
Drugs
galantamine
03
Conditions
schizophreniaschizoaffective disorderaffective disorderobsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20200207046404N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200207046404N1.